The features of clearance in recombinant factor IX (BeneFIX®)

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2516|21|5|702-707

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.21, Iss.5, 2015-09, pp. : 702-707

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The features of clearance in recombinant factor IX (BeneFIX®)

By  

HAEMOPHILIA, Vol. 1351-8216, Iss. 5, 2015-09 ,pp. : 702-707

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial

By  

HAEMOPHILIA, Vol. 21, Iss. 2, 2015-03 ,pp. : 196-203

John Wiley & Sons Inc

Access to resources Recommend Favorite

In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH‐7

By  

HAEMOPHILIA, Vol. 21, Iss. 4, 2015-07 ,pp. : e317-e321

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9‐GP), a glycoPEGylated recombinant factor IX

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 10, Iss. 11, 2012-11 ,pp. : 2305-2312

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients

By  

HAEMOPHILIA, Vol. 24, Iss. 1, 2018-01 ,pp. : 104-112

John Wiley & Sons Inc

Access to resources Recommend Favorite